Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Trends Pharmacol Sci. 2009 Mar;30(3):105-11. doi: 10.1016/j.tips.2008.11.006. Epub 2009 Feb 9.

    RGS9-2: probing an intracellular modulator of behavior as a drug target.

    Source

    Department of Pharmacology and Substance Abuse Research Center, University of Michigan, Ann Arbor, MI 48109, USA.

    Abstract

    Regulators of G-protein signaling (RGS proteins) comprise a large family of signal transduction molecules that modulate G-protein-coupled-receptor (GPCR) function. Among the RGS proteins expressed in the brain, RGS9-2 is very abundant in the striatum, a brain region involved in movement, motivation, mood and addiction. This protein negatively modulates signal transduction thus playing a key part in striatal function and resultant behavioral responses. In particular, there is evidence of important interactions with mu-opioid- and dopamine D(2)-receptor signaling pathways. Several studies indicate that manipulations of RGS9-2 levels in the striatum might greatly affect pharmacological responses. These findings indicate that treatment strategies targeting RGS9-2 levels or activity might be used to enhance responses to drugs acting at GPCRs and/or prevent undesired drug actions.

    PMID:
    19211160
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3394094
    Free PMC Article

    Images from this publication.See all images (3)Free text

    Figure I
    Figure 1
    Figure 2

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk